Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $17.75.

ATRA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Canaccord Genuity Group reduced their target price on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, January 17th. Finally, RODMAN&RENSHAW lowered Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st.

Institutional Investors Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATRA. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics during the second quarter worth $53,000. Cubist Systematic Strategies LLC purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter worth $79,000. State Street Corp boosted its position in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares during the last quarter. FMR LLC grew its holdings in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the period. Finally, Geode Capital Management LLC increased its position in Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Trading Down 4.3 %

NASDAQ ATRA opened at $10.06 on Friday. Atara Biotherapeutics has a twelve month low of $5.40 and a twelve month high of $25.00. The stock has a 50-day moving average of $11.47 and a 200 day moving average of $9.85. The stock has a market capitalization of $57.95 million, a price-to-earnings ratio of -0.39 and a beta of 0.46.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the company earned ($16.50) earnings per share. Equities analysts predict that Atara Biotherapeutics will post -10.39 EPS for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.